Inventor · disambiguated record
Chetan Padmakar Darne
Also filed as: DARNE CHETAN · DARNE CHETAN P · DARNE CHETAN PADMAKAR
14 granted patents·5 pending applications·19 citations·filing 2007–2024
86Inventor score
Files withBRISTOL MYERS SQUIBB CO14RIGEL PHARMACEUTICALS INC2AUSTIN JOEL FRANCIS1JUNO THERAPEUTICS INC1ZHANG CHENGZHI1
Top patents by PatentIndex Score
19 records- 0188US10669272B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 2, 2020·4 cites·13 claims
- 0282US9556179B2Substituted imidazoles as casein kinase 1 D/E inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 31, 2017·9 cites·15 claims
- 0380US2024400563A1Substituted pyridopyrimidinonyl compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 0478US9884868B2TGF-beta inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2016·Granted Feb 6, 2018·2 cites·36 claims
- 0574US2023151007A1Substituted pyridopyrimidinonyl compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 0667US11713316B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Aug 1, 2023·0 cites·11 claims
- 0767US8916553B2Sulfonamide compounds useful as CYP17 inhibitorsAUSTIN JOEL FRANCIS·Filed 2011·Granted Dec 23, 2014·2 cites·14 claims
- 0866US11584747B2Substituted pyridopyrimidinonyl compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Feb 21, 2023·0 cites·33 claims
- 0966US9475817B2Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Oct 25, 2016·1 cites·12 claims
- 1066US9273058B2Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Mar 1, 2016·1 cites·14 claims
- 1161US10954238B1Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Mar 23, 2021·0 cites·11 claims
- 1256US12454531B2Substituted piperazine derivatives useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Oct 28, 2025·0 cites·13 claims
- 1355US10287295B2TGF-β inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2018·Granted May 14, 2019·0 cites·20 claims
- 1455US2024108654A1Combination of a t cell therapy and a dgk inhibitorJUNO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1553US9598423B2Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Mar 21, 2017·0 cites·13 claims
- 1652US2023086933A1Substituted heteroaryl compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1743US10961239B2TGF beta receptor antagonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 30, 2021·0 cites·11 claims
- 1842US8501755B2Tetrahydropyridothienopyrimidine compounds and methods of use thereofZHANG CHENGZHI·Filed 2007·Granted Aug 6, 2013·0 cites·21 claims
- 1942US2016122358A1Novel substituted pyrazolo-piperazines as casein kinase 1 d/e inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →